Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biotechnology company developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages to treat inflammatory and autoimmune diseases. The company is currently focused on advancing its immunotherapy platform through late-stage clinical trials for knee osteoarthritis, aiming to address significant unmet medical needs. Beyond its clinical pipeline, Enlivex maintains a unique digital asset treasury strategy anchored by the Rain prediction markets protocol to drive shareholder value.

How to buy Enlivex Therapeutics on Grow →